LEGNライブシグナル | Getagraph.comで利益を最大化

買う 20068 min ago

@ $52.08

発行日: 16 4月 2024 @ 03:17

リターン: -11.98%

前回のシグナル: 4月 16 - 02:41

前回のシグナル: 売る

リターン: -1.02 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:45):

Stats
本日の出来高	433 852
平均出来高	974 846
時価総額	8.34B
EPS	$0 ( 2024-03-11 )
次の収益日	( $-0.240 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.59
ATR14	$0.0400 (0.09%)

ボリューム相関

長: 0.11 (neutral)

短: 0.59 (weak)

Signal:(28.27) Neutral

Legend Biotech Corp 相関

10 最も正の相関
AQST	0.804

10 最も負の相関
MACQU	-0.813
CFACU	-0.811

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Legend Biotech Corp 相関 - 通貨/商品

-0.59
( weak negative )

-0.39
( neutral )

0.00
( neutral )

-0.03
( neutral )

0.75
( moderate )

0.58
( weak )

Legend Biotech Corp 財務諸表

Annual	2023
収益:	$285.14M
総利益:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2023
収益:	$285.14M
総利益:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2022
収益:	$117.01M
総利益:	$51.64M (44.14 %)
EPS:	$-2.81

FY	2021
収益:	$89.79M
総利益:	$0.00 (0.00 %)
EPS:	$-2.74

Financial Reports:

No articles found.

Legend Biotech Corp

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.